medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2024, Number 3

<< Back Next >>

Acta Pediatr Mex 2024; 45 (3)

Antimicrobial resistance and its impact on pediatric infectious diseases

Alpuche ACM, Echániz AG

Language: Spanish
References: 63
Page: 240-251
PDF size: 308.19 Kb.


ABSTRACT

The success of the discovery and development of antimicrobials is a milestone in modern medicine since it is considered that there is a before and after the beginning of the clinical use of antibiotics in the treatment of infectious diseases. Antibiotic treatment has had a great impact in reducing morbidity and mortality caused by infections that can be treated, reducing the duration of illness and the potential serious complications that could arise. However, since the beginning of the clinical use of antibiotics at the end of the first half of the 20th century, it was identified that there was specificity of antibiotics to perform their action against different bacteria naturally (intrinsic resistance) and even more so, that bacteria that by species were previously sensitive to the effect of an antibiotic, over time they appeared resistant to them (acquired resistance).


REFERENCES

  1. World Health Organization. Antimicrobial Resistance. 21 November 2023. https://www.who.int/news-room/fact-sheets/detail/antimicrobial resistance. Accesso 5 demarzo 2024.

  2. World Health Organization. Global Action Plan onAntimicrobial Resistance, 2015. https://iris.who.int/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1. Acceso 5 de marzo de 2024.

  3. Bengtsson-Palme, J., Kristiansson, E., and Larsson DGJ.Environmental factors influencing the development andspread of antibiotic resistance. FEMS Microbiology Reviews,2018;42: 68–80. doi: 10.1093/femsre/fux053

  4. The World health Organization. The fight against AntimicrobialResistance requires a focus on gender. Overview, Howcan a gender focus accelerate the fight against AMR? 22March 2022. https://www.who.int/europe/publications/i/item/WHO-EURO-2021-3896-43655-61363

  5. Romandini A, Pani A, Schenardi PA, Pattarino GAC, DeGiacomo C, Scaglione F. Antibiotic Resistance in PediatricInfections: Global Emerging Threats, Predicting the NearFuture. Antibiotics (Basel). 2021 Apr 6;10(4):393. doi:10.3390/antibiotics10040393. PMID: 33917430; PMCID:PMC8067449

  6. Centers for Disease Control and Prevention. AntibioticResistance Threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-arthreats-report-508.pdf. Acceso marzo 5 2024.

  7. O’Neil, J. Antimicrobial resistance: tackling a crisis for thehealth and wealth of nations / the Review on AntimicrobialResistance. December 2014. https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Acceso marzo 5 2024.

  8. Fanelli, U.; Chiné, V.; Pappalardo, M.; Gismondi, P.; Esposito,S. Improving the quality of hospital antibiotic.use: Impacton multidrug-resistant bacterial infections in children.Front. Pharmacol. 2020;11:745.

  9. Stephan Harbarth* and Matthew H. Samore† AntimicrobialResistance Determinants and Future Control EmergingInfectious Diseases EID, 2005:11;794-801.

  10. McGowan JE Jr. Antimicrobial resistance in hospital organismsand its relation to antibiotic use. Rev Infect Dis1983;5:1033–48.

  11. World Health Day 201, Urgent action necessary to safeguarddrug treatments, 7 April 2011. https://www.who.int/news/item/07-04-2011-world-health-day-2011. Accesado22 de marzo de 2024).

  12. Diario Oficial de la Federación, SEGOB. ACUERDO por elque se declara la obligatoriedad de la Estrategia Nacionalde Acción contra la Resistencia a los Antimicrobianos. 5 dejunio del 2018, https://www.dof.gob.mx/nota_detalle.php?codigo=5525043&fecha=05/06/2018#gsc.tab=0). Acceso1 de marzo de 2024

  13. Diario Oficial de la Federación, SEGOB. ACUERDO que modificael Anexo Único del diverso por el que se declara la obligatoriedadde la Estrategia Nacional de Acción contra la Resistencia alos Antimicrobianos, publicado el 5 de junio de 2018. https://www.dof.gob.mx/nota_detalle.php?codigo=5670896&fecha=09/11/2022#gsc.tab=0. Acceso 1 de marzo de 2024.

  14. Tersigni, C., Venturini, E., Montagnani, C., Chiappini, E., deMartino, M., & Galli, L. (2019). Antimicrobial stewardshipin children: more shadows than lights? Expert Review ofAnti-Infective Therapy, 17(11), 871–876. https://doi.org/10.1080/14787210.2019.1686355

  15. Araujo da Silva AR, Albernaz de Almeida Dias DC, MarquesAF, Biscaia di Biase C, Murni IK, Dramowski A, SharlandM, Huebner J, Zingg W. Role of antimicrobial stewardshipprogrammes in children: a systematic review. J Hosp Infect.2018 Jun;99(2):117-123. doi: 10.1016/j.jhin.2017.08.003.Epub 2017 Aug 12. PMID: 28807835.

  16. Versporten A, Bielicki J, Drapier N, Sharland M, GoossensH; ARPEC project group. The Worldwide Antibiotic Resistanceand Prescribing in European Children (ARPEC) pointprevalence survey: developing hospital-quality indicatorsof antibiotic prescribing for children. J Antimicrob Chemother.2016 Apr;71(4):1106-17. doi: 10.1093/jac/dkv418.Epub 2016 Jan 8. PMID: 26747104.

  17. Aguilera-Alonso D, It Is time for pediatric antimicrobialstewardship programs. Enfermedades Infecciosas y MicrobiologíaClínica. 2021;39(3):113–114.

  18. Pana ZD, El-Shabrawi M, Sultan MA, Murray T, Alam A,Yewale V, Dharmapalan D, Klein JD, Haddad J, Thacker N,Pulungan AB, Hadjipanayis A. Fighting the hidden pandemicof antimicrobial resistance in paediatrics: recommendationsfrom the International Pediatric Association. BMJPaediatr Open. 2023 Jul;7(1):e002084. doi: 10.1136/bmjpo-2023-002084. PMID: 37500294; PMCID: PMC10387713.

  19. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, HoxhaA, Simonsen GS, Colomb-Cotinat M, et al; Burden of AMRCollaborative Group. Attributable deaths and disabilityadjustedlife-years caused by infections with antibioticresistantbacteria in the EU and the European EconomicArea in 2015: a population-level modelling analysis. LancetInfect Dis. 2019 Jan;19(1):56-66. doi: 10.1016/S1473-3099(18)30605-4. Epub 2018 Nov 5. PMID: 30409683;PMCID: PMC6300481

  20. Antimicrobial Resistance Collaborators. The burden ofantimicrobial resistance in the Americas in 2019: a crosscountrysystematic analysis. The Lancet Regional Health -Americas 2023;25:100561 Published Online 8 August 2023https://doi.org/10. 1016/j.lana.2023. 100561

  21. Domo, D., & Woogeng IN. Surveillance of the Impact of AntimicrobialResistant infections inImmunosuppressed Children’stherapy: A systematic review. medRxiv doi: https://doi.org/10.1101/2023.04.14.23288454.

  22. Wald ER. Acute Otitis Media and Acute Bacterial Sinusitis.Clinical Infectious Diseases 2011;52(S4):S277–S283. doi:10.1093/cid/cir042.

  23. Streptococcus pneumoniae: Epidemiology, Risk Factors,and Strategies for Prevention. Semin Respir Crit Care Med.2009;30:189-209. doi: 10.1055/s-0029-1202938.

  24. Bogaert D, De Groot R, Hermans PWM. Streptococcuspneumoniae colonisation: the key to pneumococcal disease.Lancet Infect Dis. 2004;4:144–154. doi: 10.1016/S1473-3099(04)00938-7.

  25. Walker CLF, Rudan I, Liu L. Global burden of childhoodpneumonia and diarrhoea. Lancet. 2013;381:1405–1416.10.1016/S0140-6736(13)60222-6

  26. Andrejko K, Ratnasiri B, Hausdorff, WP. Et al. Antimicrobialresistance in paediatric Streptococcus pneumoniae isolatesamid global implementation of pneumococcal conjugatevaccines: a systematic review and meta-regression analysis.Lancet Microbe. 2021 Sep; 2(9): e450–e460. doi: 10.1016/S2666-5247(21)00064-1.

  27. Buckley BS, Henschke N, Bergman H. Impact of vaccinationon antibiotic usage: a systematic review and meta-analysis.Clin Microbiol Infect. 2019;25:1213–1225. doi: 10.1016/j.cmi.2019.06.030.

  28. Lewnard, J.A., Lo, N.C., Arinaminpathy, N. et al. Childhoodvaccines and antibiotic use in low- and middleincomecountries. Nature 581, 94–99 (2020). https://doi.org/10.1038/s41586-020-2238-4.

  29. Andrejko K, Ratnasiri B, Hausdorff WP, et al. Antimicrobialresistance in paediatric Streptococcus pneumoniae isolatesamid global implementation of pneumococcal conjugatevaccines: a systematic review and meta-regression analysis.Lancet Microbe. 2021 Sep; 2(9): e450–e460. Publishedonline 2021 Sep. doi: 10.1016/S2666-5247(21)00064-1

  30. Centers for Disease Control and Prevention Effects of newpenicillin susceptibility breakpoints for Streptococcuspneumoniae—United States, 2006–2007, MMWR MorbMortal Wkly Rep, 2008;57:1353-1355.

  31. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ,Hicks LA, et al ; Infectious Diseases Society of America. IDSAclinical practice guideline for acute bacterial rhinosinusitisin children and adults. Clin Infect Dis. 2012 Apr;54(8):e72-e112. doi: 10.1093/cid/cir1043. Epub 2012 Mar 20. PMID:22438350.

  32. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL,Scheld WM, Whitley RJ. Practice guidelines for the managementof bacterial meningitis. Clin Infect Dis. 2004 Nov1;39(9):1267-84. doi: 10.1086/425368. Epub 2004 Oct 6.PMID: 15494903.

  33. van de Beek D, Cabellos C, Dzupova O, Esposito S, KleinM, Kloek AT, Leib SL, Mourvillier B, Ostergaard C, PaglianoP, Pfister HW, Read RC, Sipahi OR, Brouwer MC; ESCMIDStudy Group for Infections of the Brain (ESGIB). ESCMIDguideline: diagnosis and treatment of acute bacterial meningitis.Clin Microbiol Infect. 2016 May;22 Suppl 3:S37-62.doi: 10.1016/j.cmi.2016.01.007. Epub 2016 Apr 7. PMID:27062097.

  34. GIVEBPVac. https://www.insp.mx/lineas-de-investigacion/medicamentos-en-salud-publica/sireva.html.

  35. JacobyGA, Medeiros A. More extended-spectrumbetalactamases.Antimicrob Agents Chemother 1991;35:1697–704.

  36. Jacoby GA. Extended spectrum beta-lactamases and otherenzymes provided resistance to oximino-betalactams.Infect Dis Clin North Am 1997; 11:875–87. doi: 10.1016/s0891-5520(05)70395-0

  37. Winokur PL, Canton R, Casellas JM, Legakis N. Variationsin the prevalence of strains expressing an extendedspectrum b-lactamase phenotype and characterizationof isolates from Europe, the Americas and the WesternPacific Region. Clin Infect Dis 2001;32(Suppl 2): S94–S103.doi: 10.1086/320182 .

  38. Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J,Srinivasan A, Kallen A, Limbago B, Fridkin S; NationalHealthcare Safety Network (NHSN) Team and ParticipatingNHSN Facilities. Antimicrobial-resistant pathogensassociated with healthcare-associated infections:summary of data reported to the National HealthcareSafety Network at the Centers for Disease Control andPrevention, 2009-2010. Infect Control Hosp Epidemiol.2013 Jan;34(1):1-14. doi: 10.1086/668770. Epub 2012Nov 27. PMID: 23221186.

  39. Stone PW, Gupta A, Loughrey M, Della-Latta P, Cimiotti J,Larson E, Rubenstein D, Saiman L. Attributable costs andlength of stay of an extended-spectrum beta-lactamaseproducingKlebsiella pneumoniae outbreak in a neonatalintensive care unit. Infect Control Hosp Epidemiol. 2003Aug;24(8):601-6. doi: 10.1086/502253. PMID: 12940582.

  40. Ramphal R. Extended-spectrum β-lactamases and clinicaloutcomes: Current data. Clin Infect Dis 2006; 42(suppl 4):S164–72. doi: 10.1086/500663

  41. Logan LK, Braykov NP, Weinstein RA, Laxminarayan R;CDC Epicenters Prevention Program. Extended-Spectrumβ-Lactamase-Producing and Third-Generation Cephalosporin-Resistant Enterobacteriaceae in Children: Trends in theUnited States, 1999-2011. J Pediatric Infect Dis Soc. 2014Dec;3(4):320-8. doi: 10.1093/jpids/piu010. Epub 2014 Mar19. PMID: 26625452.

  42. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobialresistance pattern comparisons among bloodstreaminfection isolates from the SENTRY Antimicrobial SurveillanceProgram (1997–2002). Diagn Microbiol Infect Dis.2004;50: 59–69. doi: 10.1016/j.diagmicrobio.2004.05.003.

  43. Flokas ME, Karanika S, Alevizakos M, Mylonakis E. Prevalenceof ESBL-Producing Enterobacteriaceae in PediatricBloodstream Infections: A Systematic Review and Meta-Analysis. PLoS ONE. 2017;12(1): e0171216. doi:10.1371/journal.pone.0171216.

  44. Alcantar-Curiel D, Tinoco JC, Gayosso C, Carlos A, Daza C,Perez-Prado MC, Salcido L, Santos JI, Alpuche-Aranda CM.Nosocomial bacteremia and urinary tract infections causedby extended-spectrum beta -lactamase-producing Klebsiellapneumoniae with plasmids carrying both SHV-5 andTLA-1 genes. Clin Infect Dis. 2004 Apr 15;38(8):1067-74.doi: 10.1086/382354. Epub 2004 Mar 24. PMID: 15095209.

  45. Gonzalez-Vertiz A, Alcantar-Curiel D, Cuauhtli M, DazaC, Gayosso C, Solache G, Horta C, Mejia F, Santos JI,Alpuche-Aranda C. Multiresistant extended-spectrumbeta-lactamase-producing Klebsiella pneumoniae causingan outbreak of nosocomial bloodstream infection. InfectControl Hosp Epidemiol. 2001 Nov;22(11):723-5. doi:10.1086/501854. PMID: 11842996.

  46. Martinez-Aguilar G, Alpuche-Aranda CM, Anaya C, Alcantar-Curiel D, Gayosso C, Daza C, Mijares C, Tinoco JC, Santos JI.Outbreak of nosocomial sepsis and pneumonia in a newbornintensive care unit by multiresistant extended-spectrumbeta-lactamase-producing Klebsiella pneumoniae: highimpact on mortality. Infect Control Hosp Epidemiol. 2001Nov;22(11):725-8. doi: 10.1086/501855. PMID: 11842997.

  47. Silva J, Gatica R, Aguilar C, Becerra Z, Garza-Ramos U,Velázquez M, Miranda G, Leaños B, Solórzano F, EchánizG. Outbreak of infection with extended-spectrum betalactamase-producing Klebsiella pneumoniae in a Mexicanhospital. J Clin Microbiol. 2001 Sep;39(9):3193-6. doi:10.1128/JCM.39.9.3193-3196.2001. PMID: 11526149;PMCID: PMC88317.

  48. Silva J, Aguilar C, Becerra Z, Lopez-Antunano F, Garcı ́a R.Extended- spectrum beta-lactamase in clinical isolatesof enterobacteria in Me ́ xico. Microb Drug Resist 1999;5(3):189–93.

  49. Miranda-Romero, AL., Silva-Sanchez, J., Garza–Ramos, U.Molecular characterization of ESBL-producing Escherichia coliisolates from hospital- and community-acquired infections inNW Mexico. Diagn Microbiol Infect Dis. 2017;87(1):49–52.https://doi.org/10.1016/j.diagmicrobio.2016.10.006

  50. Barrios H, Garza-Ramos U, Mejia-Miranda I, Reyna-FloresF, Sánchez-Pérez A, et al; Bacterial Resistance Consortium.ESBL-producing Escherichia coli and Klebsiella pneumoniae:The most prevalent clinical isolates obtained between2005 and 2012 in Mexico. J Glob Antimicrob Resist. 2017Sep;10:243-246. doi: 10.1016/j.jgar.2017.06.008. Epub2017 Jul 21. PMID: 28739224.

  51. Boletín Infecciones Asociadas a la Atención de la Salud(IAAS) Red Hospitalaria de Vigilancia Epidemiológica(RHOVE) 2022. Secretaría de Salud, Dirección General deEpidemiología. Boletin Infecciones Asociadas a la Atenciónde la Salud (IAAS) Red Hospitalaria de Vigilancia Epidemiologica(RHOVE) 2022. Secretar√≠a de Salud, DirecciónGeneral de Epidemiología. Acceso 8 de abril de 2024.

  52. Kaarme J, Riedel H, Schaal W, Yin H, Nevéus T, Melhus Å.Rapid Increase in Carriage Rates of EnterobacteriaceaeProducing Extended-Spectrum β-Lactamases in HealthyPreschool Children, Sweden. Emerg Infect Dis. 2018Oct;24(10):1874-1881. doi: 10.3201/eid2410.171842.PMID: 30226162; PMCID: PMC6154144.

  53. Islam S, Selvarangan R, Kanwar N, McHenry R, Chappell JD,Halasa N, Wikswo ME, Payne DC, Azimi PH, McDonald LC,Gomez-Duarte OG. Intestinal Carriage of Third-GenerationCephalosporin-Resistant and Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Healthy US Children. J PediatricInfect Dis Soc. 2018 Aug 17;7(3):234-240. doi: 10.1093/jpids/pix045. PMID: 28992133; PMCID: PMC5820225.

  54. Logan LK, Weinstein RA. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolutionof a Global Menace. The Journal of Infectious Diseases.2017;215(suppl_1):S28-S36. doi:10.1093/infdis/jiw282.

  55. Chiotos K., Tamma PD., Flett KB., Multicenter study of therisk factors for colonization or infection with carbapenemresistantEnterobacteriaceae in children. Antimicrob AgentsChemother, 2017;61:e01440-17. https://doi.org/10.1128/AAC .01440-17.

  56. Logan, LK. Carbapenem-Resistant Enterobacteriaceae: AnEmerging Problem in Children. Clinical Infectious Diseases,2012;55 (6), 15:852-859, 859 https://doi.org/10.1093/cid/cis543

  57. Torres-Gonzalez, P., Cervera-Hernandez, ME., Niembro-Ortega, MD., et al. Factors Associated to Prevalence andIncidence of Carbapenem- Resistant EnterobacteriaceaeFecal Carriage: A Cohort Study in a Mexican Tertiary CareHospital. PLoS ONE, 2015;10(10): e0139883. doi:10.1371/journal. pone.0139883

  58. Alcantar-Curiel MD., Garcıa-Torres LF., Gonzalez-ChavezMI.,Morfin OR,Gayosso Vazquez C. et al. MolecularMechanisms Associated with Nosocomial CarbapenemresistantAcinetobacter baumannii in Mexico. Archivesof Medical Research, 2014;45:53e560. DOI:10.1016/j.arcmed.2014.10.006.

  59. Cruz-López F., Rincón-Zuno J., Morfin-Otero R., Rodriguez-Noriega Eduardo, Corte- Rojas RE., Feliciano-Guzman JM., et al. Drug Resistance Analysisof Pathogens Isolated from Pediatric Patients inMexico, J Pediatr Infect Dis 2023;18(06): 273-282DOI: 10.1055/s-0043-1771528.

  60. Bocanegra-Ibarias P, Garza-González E, Padilla-Orozco M,Mendoza-Olazarán S, Pérez-Alba E, et al The successfulcontainment of a hospital outbreak caused by NDM-1-producing Klebsiella pneumoniae ST307 using activesurveillance. PLoS One. 2019 Feb 13;14(2):e0209609. doi:10.1371/journal.pone.0209609. PMID: 30759100; PMCID:PMC6373926.

  61. Organización Panamericana de la Salud. Es fundamental laimplementación de Programas de Optimización de Antimicrobianos(PROA). 17 de Noviembre de 2021. https://www.paho.org/es/noticias/17-11-2021-es-fundamental-implementacion-programas-optimizacion-antimicrobianos-proa.

  62. World health Organization. Antimicrobial stewardship programmesin health-care facilities in low- and middle-incomecountries. A WHO practical toolkit. 2020. https://iris.who.int/bitstream/handle/10665/335947/9789240003057-spa.pdf?sequence=1. Acceso 8 de abril de 2024.

  63. World health Organization. Guía AWaRe (Acceso, Precaucióny Reserva) de la OMS para el uso de antibióticos. Infografíasen Anexo web. 2022. https://iris.who.int/bitstream/handle/10665/375875/WHO-MHP-HPS-EML-2022.02-spa.pdf?sequence=1&isAllowed=y. Acceso 8 de abril de 2024.




2020     |     www.medigraphic.com